A preference trial with rizatriptan 10 mg and ibuprofen 400 mg in migraine patients in the general practice

INTERVENTION: Thirty‐five triptan naive patients treat three attacks within each crossover period with either: 1. Rizatriptan 10 mg 2. Ibuprofen 400 mg Preference is measured after the second period on a 10 cm scale. CONDITION: Migraine ; Nervous System Diseases ; Migraine PRIMARY OUTCOME: Direction and strength of patient preference on a 10 cm scale ranging from ‐5 (strong preference for treatment 1) to +5 (strong preference for treatment 2) where 0 indicates no preference. SECONDARY OUTCOME: 1. Pain free rate at 2 hours postdose; 2. Migraine disability assessment (MIDAS) score at visit 1 INCLUSION CRITERIA: 1. At least 18 years of age at visit 1 2. Current history of migraine with or without aura according to the International Headache Society (IHS) criteria 3. Experienced an average of at least one migraine attack per month for six months prior to entry to the study 4. Naïve to the use of 5HT1 agonists and ergotamine 5. Willing and able to understand and complete questionnaires 6. Willing and able to give informed consent prior to entry into the study